ArticleMedical acupuncture2025
Effectiveness of Transcutaneous Electrical Acupoint Stimulation in the Treatment of Post-COVID Severe Dyspnea: A Case Report.
Article in Medical acupuncture, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Long COVID, or post-COVID syndrome, refers to signs, symptoms, and conditions that persist or emerge following an acute coronavirus disease (COVID-19) infection. The most frequent symptoms are fatigue and dyspnea, with approximately 10-20% of patients recovering from COVID-19. Currently, there are no specific medical recommendations, except for symptomatic treatment. Objective: To evaluate the use of transcutaneous electrical acupoint stimulation (TEAS) for the treatment of post-COVID severe dyspnea. Methodology: This is a case report of successful treatment using TEAS in a patient with severe dyspnea after recovery from COVID-19. Results: A female adult patient experienced progressive dyspnea after recovering from COVID-19 a year prior. One session of TEAS successfully relieved severe dyspnea. No adverse effects or recurrence of dyspnea were reported at the 6-month follow-up. Conclusion: TEAS is a safe, simple, and effective treatment for overcoming post-COVID severe dyspnea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.